**Chapter 3**

*Drug Design - Novel Advances in the Omics Field and Applications*

[84] Limdi NA, Veenstra DL. Warfarin pharmacogenetics. Pharmacotherapy:

[86] Haase CG, Zuhlsdorf M, Kuhlmann J. The implication of pharmacogenomics/ pharmacogenetics on the treatment of neurological diseases. Aktuelle Neurologie. 2002;**29**(7):333-337

[87] Wadelius M, Pirmohamed M. Pharmacogenetics of warfarin: Current

status and future challenges. The Pharmacogenomics Journal.

[88] Li T, Chang CY, Jin DY, Lin PJ, Khvorova A, Stafford DW. Identification of the gene for vitamin

K epoxide reductase. Nature. 2004;**427**(6974):541-544

of Clinical Pharmacology. 2010;**70**(2):164-170

[91] Vegter S, Boersma C, Rozenbaum M, Wilffert B,

and genomic screening

2008;**26**(7):569-587

[89] Lurie Y, Loebstein R, Kurnik D, Almog S, Halkin H. Warfarin and vitamin K intake in the era of pharmacogenetics. British Journal

[90] Dervieux T, Meshkin B, Neri B. Pharmacogenetic testing: Proofs of principle and pharmacoeconomic implications. Mutation Research, Fundamental and Molecular Mechanisms of Mutagenesis. 2005;**573**(1-2):180-194

Navis G, Postma MJ. Pharmacoeconomic

evaluations of pharmacogenetic

programmes. PharmacoEconomics.

2007;**7**(2):99-111

Pharmacology and Drug Therapy.

[85] Chasman DI, Ridker PM. Pharmacogenetics: The outlook for genetic testing in statin therapy. Nature Clinical Practice. Cardiovascular

The Journal of Human

2008;**28**(9):1084-1097

Medicine. 2005;**2**(1):2-3

**30**
